
    
      This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 2-arm,
      analog classroom study to evaluate the efficacy and safety of 200 mg/day SPN-812 compared to
      placebo in the treatment of children aged 6 through 11 years with ADHD.
    
  